Is IVIXF or JEPI a better dividend investment in 2026?

IVIXF currently yields 5420.05% with a 5% 5-year dividend growth rate. JEPI yields 8.40% with 2.1% growth. The better choice depends on your goal: IVIXF offers higher current income.

What is the dividend yield difference between IVIXF and JEPI?

IVIXF has a forward dividend yield of 5420.05% ($2.00/share annually). JEPI yields 8.40% ($4.76/share annually). The yield gap is 5411.65 percentage points.

Home › Compare › IVIXF vs JEPI

IVIXF vs JEPI: Dividend Comparison 2026

IVIXF yields 5420.05% · JEPI yields 8.40%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 IVIXF wins by $136326195118802.20M in total portfolio value

INVESTMENT

TIME HORIZON10 years

IVIXF

● Live price

5420.05%

Share price

$0.04

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$136326195118802.23M

Annual income

$131,551,666,493,773,860,000.00

Full IVIXF calculator →

JEPI

JPMorgan Equity Premium Income ETF

● Live price

8.40%

Share price

$56.68

Annual div

$4.76

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$29.0K

Annual income

$1,528.62

Full JEPI calculator →

Portfolio growth — IVIXF vs JEPI

📍 IVIXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	IVIXF	JEPI
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, IVIXF + JEPI cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

IVIXF pays

JEPI pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IVIXF

Annual income on $10K today (after 15% tax)

$460,704.61/yr

After 10yr DRIP, annual income (after tax)

$111,818,916,519,707,770,000.00/yr

JEPI

Annual income on $10K today (after 15% tax)

$714.16/yr

After 10yr DRIP, annual income (after tax)

$1,299.33/yr

At 15% tax rate, IVIXF beats the other by $111,818,916,519,707,770,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IVIXF + JEPI for your $10,000?

IVIXF: 50%JEPI: 50%

100% JEPI50/50100% IVIXF

Portfolio after 10yr

$68163097559401.13M

Annual income

$65,775,833,246,886,930,000.00/yr

Blended yield

96.50%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IVIXF buys

JEPI buys

No recent congressional trades found for IVIXF or JEPI in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricIVIXFJEPI

Forward yield	5420.05% ✓	8.40%
Annual dividend / share	$2.00	$4.76 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$136326195118802.23M ✓	$29.0K
Annual income after 10y	$131,551,666,493,773,860,000.00 ✓	$1,528.62
Total dividends collected	$136003983287005.17M ✓	$11.7K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: IVIXF vs JEPI ($10,000, DRIP)

Year	IVIXF Portfolio	IVIXF Income/yr	JEPI Portfolio	JEPI Income/yr	Gap
1← crossover	$552,705	$542,005.42	$11,260	$840.19	+$541.4K → IVIXF
2	$28,588,529	$27,997,133.96	$12,641	$907.94	+$28.58M → IVIXF
3	$1,383,995,048	$1,353,405,322.61	$14,150	$978.20	+$1383.98M → IVIXF
4	$62,714,057,337	$61,233,182,635.19	$15,795	$1,050.85	+$62714.04M → IVIXF
5	$2,660,288,543,813	$2,593,184,502,462.66	$17,584	$1,125.74	+$2660288.53M → IVIXF
6	$105,651,330,702,723	$102,804,821,960,842.73	$19,526	$1,202.74	+$105651330.68M → IVIXF
7	$3,928,761,972,612,137	$3,815,715,048,760,222.50	$21,628	$1,281.69	+$3928761972.59M → IVIXF
8	$136,812,745,737,264,320	$132,608,970,426,569,340.00	$23,898	$1,362.43	+$136812745737.24M → IVIXF
9	$4,462,176,285,073,260,500	$4,315,786,647,134,387,700.00	$26,347	$1,444.79	+$4462176285073.23M → IVIXF
10	$136,326,195,118,802,240,000	$131,551,666,493,773,860,000.00	$28,982	$1,528.62	+$136326195118802.20M → IVIXF

IVIXF vs JEPI: Complete Analysis 2026

IVIXF — Stock

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.

Full IVIXF Calculator →

JEPI — ETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →

📬

Get this IVIXF vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IVIXF vs SCHD IVIXF vs O IVIXF vs KO IVIXF vs MAIN IVIXF vs JEPQ IVIXF vs XYLD IVIXF vs DIVO IVIXF vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.